Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update

• Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results

• Q1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™

Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient lives

Strategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in Pittsburgh

The Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilities

Company has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions

TAMPA, FL / ACCESS Newswire / May 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology company, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx with licensed blockchain-enabled smart contract technology through PharmacyChain, reported financial results for the first quarter ended March 31, 2026 and provided a second quarter 2026 business update from its President & Interim-CEO Prashant Patel, RPh.

"The Company's first quarter focus on expanding direct sales from its Wellgistics Pharmacy segment led to sequential quarter over quarter growth that is now beginning to reach critical mass in the second quarter," said Prashant Patel, RPh, President & Interim-CEO Prashant Patel. "We believe the sequential growth in Wellgistics Pharmacy revenue, together with our Kare Pharmtech joint venture, provides a foundation for continued expansion of our direct-to-patient initiatives. As we work to onboard patient lives available through the joint venture and prepare for the targeted August 2026 launch of the Health Lives Here initiative with Tollo Health and NFL Alumni Health, we are also continuing to advance the integration of PharmacyChain functionality with our EinsteinRx pharmacy dispensing AI hub. As we onboard an increasing percentage of the 200,000+ patient lives through the joint venture, we are preparing to support a significant ramp up in prescription dispending through our direct-to-consumer initiatives with Tollo Health coming from that planned August 2026 launch through the partnership with NFL Alumni Health of the "Health Lives Here initiative" that was revealed at the 2026 NFL Draft in Pittsburgh."

Schreibe Deinen Kommentar